Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p53-Y220C-tPRIMEs
- Development stage
- Preclinical
- Lead developer
- Photys Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
p53-Y220C-tPRIMEs is a preclinical bifunctional small molecule developed by Photys Therapeutics for the treatment of p53-Y220C-mutant cancers. Utilizing the proprietary tPRIME™ (transcriptional upregulation via induced proximity) platform, the molecule acts as an induced-proximity agent that simultaneously engages the Y220C mutant form of the p53 tumor suppressor and Bromodomain and Extra-Terminal (BET) family proteins, including BRD2, BRD3, and BRD4. By recruiting BET proteins to the mutant p53, the drug aims to modulate and restore transcriptional activity that is typically lost or altered in p53-mutant oncology indications.
- Other names
- p53-Y220C-BET bifunctionalsp-53-Y220C-BET bifunctionalsp 53-Y220C-BET bifunctionals
02
Targets
BRD4 (Bromodomain-containing protein 4)TP53 Y220C (Tumor suppressor protein p53 Y220C mutant)BRD2 (Bromodomain-containing protein 2)BRD3 (Bromodomain-containing protein 3)
Beyond the preview
Go deeper on p53-Y220C-tPRIMEs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p53-Y220C-tPRIMEs.